Description: Vaxil Bio Ltd., an immuno-oncology biotechnology company, engages in the researches and develops immunotherapies for cancer and other diseases in Israel. Its pipeline includes its lead candidate ImMucinTM, a neoantigen-like peptide product and antibodies developed to treat cancer and infectious diseases. The company was founded in 2006 and is headquartered in Toronto, Canada.
Home Page: www.vaxil-bio.com
3400 One First Canadian Place
Toronto,
ON
M5X 1A4
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Gadi Levin B.Com., C.A., CPA, M.B.A., MBA | Chairman & CFO |
| Dr. Yuval Avnir Ph.D. | Head of R&D & CEO |
| Dr. Riva Kovjazin M.D. | Sr. Scientist & Member of Scientific Advisory Board |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.6819 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |